MARY PAT THYNGE, Magistrate Judge.
Plaintiff Finjan, Inc. ("Finjan") filed this patent infringement action on October 1, 2018 against defendants Rapid7, Inc. and Rapid7 LLC ("defendants").
Finjan is a Delaware Corporation with its principal place of business in Palo Alto, California.
Rapid7, Inc. is a Delaware Corporation with its principal place of business in Boston, Massachusetts.
Finjan has numerous patents issued by the United States Patent and Trademark Office ("PTO"), where all rights, title, and interest of the patents have been assigned to it and it is the sole owner.
Moshe Rubin, Moshe Matitya, Artem Melnick, Shlomo Touboul, Alexander Yermakov and Amit Shaked were issued the '305 Patent on July 5, 2011, and the '408 Patent on July 17, 2012.
The PTO issued to David Gruzman and Yuval Ben-Itzhak the '289 Patent on July 13, 2010, and the '154 Patent on March 20, 2012. The '289 Patent is generally directed towards a system and method for inspecting dynamically generated executable code, while the '154 Patent is generally directed towards a gateway computer protecting a client computer from dynamically generated malicious content.
On November 3, 2009, the '918 Patent issued to Yuval Ben-Itzhak, and it generally addresses a system and method for enforcing a security context on a Downloadable.
Thereafter, the PTO issued to Yigal Mordechai Edery, Nimrod Itzhak Vered, David R. Kroll and Shlomo Touboul the '086 Patent on December 13, 2011, and the '494 Patent on March 18, 2014. The '086 Patent is generally directed towards computer networks and, more particularly, provides a system that protects devices connected to the Internet from undesirable operations from web-based content.
Finjan asserts these patents result from years of research and development efforts, supported by a dozen inventors and over $65 million in R&D investments.
Finjan claims it generated millions of dollars in product sales and related services and support revenues through 2009.
Finjan notes that it had numerous contacts with defendants both in person and in writing, to specifically identify defendants' continued infringing behavior of the Asserted Patents, specifically the '305, '086, and '494 Patents.
Finjan claims that from approximately May 11, 2016 to January 4, 2018, it attempted to engage in good faith negotiations with defendants regarding their ongoing alleged infringement of its patent portfolio.
Finjan alleges defendants knew they infringed the Asserted Patents well before this action was filed, and acted egregiously and willfully by continuing their infringing conduct and, on information and belief, took no action to avoid infringement.
Defendants are closely related companies that operate as a single business entity directed and controlled by Rapid7, Inc. They make, use, sell, and import the alleged infringing products and services that utilize InsightIDR, InsightVM (Nexpose), InsightAppSec, AppSpider, Metasploit and Komand technologies, including Rapid7 Insight Platform products (collectively, the "Accused Products").
Defendants' products are all interrelated through the Rapid7 Insight Platform.
InsightIDR receives data from a network's endpoints, cloud and virtual services, and utilizes a combination of scanning technology, machine learning, live threat feeds, and a library of behavioral threat analytics in order to scan and monitor network events for both new and existing threats.
InsightVM (Nexpose) receives data from a network's endpoints, cloud and virtual services, and utilizes a combination of scanning technology, live threat feeds, and a library of threat analytics in order to scan and monitor the network for both new and existing vulnerabilities. InsightVM uses RealRisk to assign a risk score to each detected threat.
InsightAppSec searches and assesses web applications to detect SQL Injection, XSS, and CSRF threats.
Metasploit is a penetration testing software that utilizes a database of exploits.
Finjan alleges that defendants have directly and indirectly infringed the Asserted Patents, by making, using, importing, selling, and offering for sale the defendants' products and services that utilize InsightIDR, InsightVM (Nexpose), Metasploit and Komand technologies, including Rapid7 Insight Platform products.
In reviewing a motion to strike pursuant to FED. R. CIV. P. 12(f), "[t]he court may strike from a pleading . . . any redundant, immaterial, impertinent, or scandalous matter."
Although motions to strike "serve to `clean up the pleadings, streamline litigation, and avoid unnecessary forays into immaterial matters,'" as a general matter, these motions are disfavored.
Therefore, even where the challenged material is redundant, immaterial, impertinent, or scandalous, a motion to strike should not be granted unless the presence of the surplusage will prejudice the adverse party.
FED. R. CIV. P. 8 addresses the requirements of pleading affirmative defenses. An affirmative defense is "a pleading subject to Rule 8(a), and therefore must include a short and plain statement of the defense."
Finjan contends that defendants' Third, Fourth, Fifth, and Sixth Affirmative Defenses, based on inequitable conduct, and Seventh Affirmative Defense, based on unclean hands, fall short of the heightened pleading standard under FED. R. CIV. P. 9(b).
Finjan contends defendants failed to allege facts showing the plausibility of "but-for materiality" and "specific intent to deceive the PTO." Finjan maintains that defendants' affirmative defenses fail at a fundamental level, and their factual allegations do not show any misrepresentation to, or reliance by, the PTO on but-for materiality and or evidence of specific intent to deceive the PTO.
Applicants for patents and their legal representatives owe a duty of candor, good faith, and honesty in their dealings with the PTO.
Inequitable conduct, like similar allegations of fraud or mistake, must be pled with particularity under Rule 9(b).
To properly plead inequitable conduct in a patent case, Rule 9(b) requires identification of the specific who, what, when, where, why, and how of the material misrepresentation or omission committed before the PTO.
Finjan claims that the court should strike defendants' Third Affirmative defense regarding statements to the PTO concerning inventorship of the '494 Patent, because the Touboul Declaration is accurate and defendants did not allege any facts to the contrary. Finjan further contends that defendants' claims are baseless and not facially plausible because there are no facts alleged that indicate a misrepresentation. Finjan argues that defendants' Fourth Affirmative defense fails because it does not provided a sufficient factual basis that Ms. Bey submitted incorrect information to the PTO or shows a specific intent to deceive. Finjan notes that defendants' contentions were a single, conclusory sentence that "Ms. Bey's representation that the delayed priority claim was `unintentional' was false and intended to deceive the USPTO."
On May 7, 2013, Finjan submitted a declaration from one of the named inventors of the '494 Patent, Shlomo Touboul. Touboul's Declaration provides:
Defendants allege that Touboul's declaration is false regarding the conception date of the claimed inventions in the '494 Patent, and his assertion as the sole inventor of these claims.
Defendants further contend that Finjan's attorney submitted a petition to accept unintentionally delayed claims of priority under 35 U.S.C. §§ 119(e) and 120 for the benefit of a prior-filed application under 37 C.F.R. § 1.78(a)(3) to extend the chain priority.
Defendants argue that Finjan submitted the application without making a claim and Ms. Bey engaged in a pattern of petitioning for unintentionally delayed priority claims.
Defendants emphasize Mr. Touboul's declaration, arguing his assertion as the sole inventor and the conception date were incorrect. However, Touboul merely stated that "my sole invention was in my mind and developed by at least November 18, 1996. The remaining pending dependent claims were co-invented by or with one or more of the listed inventors." He did not assert to have invented all claims himself, but only those listed in his declaration. Moreover, the '494 Patent identifies the multiple inventors.
Defendants contend that the '494 Patent is unenf orcable based on inequitable conduct. Defendants claim that Finjan and Ms. Bey delayed claiming priority to maximize the value of the '494 Patent during pre-suit licensing negotiations and only attempted to correct the claim of priority to overcome invalidity attacks on this patent.
Defendants further allege that Ms. Bey's misrepresentation of a material fact to the PTO regarding with the '494 Patent is also a part of an overarching scheme which Finjan deliberately planned and carefully executed to defraud the PTO.
In light of defendants' contentions noted above, they pled sufficient facts with particularity showing inequitable conduct. "In all averment of fraud or mistake, the circumstances constituting fraud or mistake shall be stated with particularity."
Finjan claims that defendants' Fifth Affirmative defense does not meet the heightened pleading standard because its allegations are not supported by the '154 Patent's file history and fail to show materiality and specific intent.
Finjan claims defendants' allegations that its attorney committed inequitable conduct by her filing of petitions to the Patent Office is facially implausible in view of the record. Similar to the '494 Patent, Finjan maintains Ms. Bey merely corrected an error in the printed patent through the '154 Patent Petition to correct the '154 Patent's priority claim, which was not reflected in the printed patent, through a certificate of correction.
Finjan further contends that defendants' answer fails to allege any but-for materiality regarding Ms. Bey's statements in the '154 Patent Petition, nor is there per se materiality because their allegations do not show an unusually frequent pattern of petitioning to correct priority claims. Finjan asserts that the petitions in the '494, '086, '633 patents involve correcting the same issue, perfecting the priority claim chain related to their common parent, U.S. Provisional Application No. 60/030,639. As a result, Finjan argues that Ms. Bey's multiple submissions were to correct the same mistake so that the Finjan patent portfolio would have consistent priority claims.
Defendants adequately pled facts to support its inequitable conduct claims. Defendants asserted that Ms. Bey alleged unintentionally delayed claim of priority in her petitions under 35 U.S.C. § 120 for the Benefit of a Prior-Filed Application under 37 C.F.R. section 1.78(a)(3) by identifying October 16, 2013 as the date when this occurred, and why the withheld information was material and not cumulative. Further, defendants properly addressed why and how an examiner would use the information in assessing patentability. Their pleading identified the required facts to meet the heightened pleading standard of FED. R. CIV. P. 9(b).
Finjan contends that defendants' Sixth Affirmative defense does not meet the Rule 9(b) or Therasense heightened pleading standard because its allegations are not supported by the '086 Patent's file history and there are no facts alleged which are sufficient to show materiality and specific intent. Finjan asserts that this Affirmative defense mirrors defendants' Fourth and Fifth Affirmative defenses, namely that Ms. Bey, Finjan's counsel, committed inequitable conduct when she made the filing. Finjan further argues that defendants also failed to adequately allege a factual basis to support specific intent to deceive the PTO on the part of Ms. Bey, and that these are merely conclusory allegations of intent absent any factual support.
In Therasense, the Court of Appeals for the Federal Circuit addressed the heightened pleading standard for inequitable conduct based on nondisclosure of a reference to the PTO. Under Therasense, a challenger must plead, both that: (1) "the patentee acted with the specific intent to deceive the PTO"; and (2) the nondisclosed reference was a "but for" cause of the PTO's allowance of the claims.
The "unclean hands doctrine is rooted in the historical concept that the court as a `vehicle for affirmatively enforcing the requirements of conscience and good faith,' requires the parties to have `acted fairly and without fraud or deceit as to the controversy in issue.'"
Finjan contends that Rapid7 failed to plead adequately facts demonstrating that its counsel's actions during prosecution constituted an egregious act of misconduct or were done in bad faith. Rapid7 claims that Finjan misrepresented a material fact and violated its duty of candor by filing a petition to claim a certain priority date.
Finjan asserts the prosecution of '494, '086, and '154 Patents were well within the PTO's procedures, and defendants provide no factual basis for their unsupported allegation that on multiple occasions Finjan waited to see if a patent would be granted or provided with a later priority date, and only when it was clear that the patent would not be granted, did Finjan seek to `correct' its `unintentionally' delayed priority claim to moot the asserted prior art.
Finjan claims that Rapid7 merely walks through the prosecution history of the '822 Patent, and pled no facts showing how the steps during prosecution constituted "an egregious act of misconduct" or were made in bad faith. Finjan also contends that there is no reasonable inference that the prosecution with continuations and related filings from an initial application was done in bad faith. It notes that defendants merely pled Finjan prosecuted a family of patents over a period of time and it corrected the priority chain of the '822 Patent, which is allowed under the MPEP, and does not constitute unclean hands or egregious misconduct or bad faith.
Overall, Finjan's arguments are directed to disputed issues of fact, rather than the adequacy of Defendants' factual support in this affirmative defense.
Defendants counter that Finjan, through Ms. Bey, has an unusually frequent practice of petitioning for allegedly "unintentionally" delayed claims of priority after one of its applications is rejected over prior art that predates its filing, but post-dates the belatedly asserted priority document.
Defendants further argue that on multiple occasions Finjan waited to determine whether a patent would be granted or given a later priority date thereby benefitting from a later expiration date, and when it is apparent that neither will occur, then Finjan proceeds to correct.
Defendants allege Ms. Bey misrepresented a material fact to the PTO and violated her duty of candor when she represented that the delayed claim of priority in the '822 Patent was unintentional. Defendants contend that Finjan intentionally delayed claiming priority of the '822 Patent to enable it to benefit from a later expiration date unless an earlier priority date was required to overcome prior art.
Defendants pled sufficient facts regarding their defense of unclean hands. The elements of misrepresentation of material fact and violation of Finjan's duty of candor are sufficiently supported by factual allegations which demonstrate bad faith misrepresentation or egregious misconduct.
For the foregoing reasons, I recommend that Plaintiff's motion to strike defendants' Third, Fourth, Fifth, Sixth, and Seventh affirmative defenses (D.I. 18) be DENIED.
This Report and Recommendation is filed pursuant to 28 U.S.C. §636(b)(1)(B), FED R. CIV. P. 72(b)(1), and D. DEL. LR 72.1. The parties may serve and file specific written objections within fourteen (14) days after being served with a copy of this Report and Recommendation. Objections and responses are limited to ten (10) pages each.
The parties are directed to the Court's Standing Order in Non-Pro Se matters for Objections Filed under FED. R. CIV. P. 72, dated October 9, 2013, a copy of which is available on the Court's website, www.ded.uscourts.gov.